Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis.

EClinicalMedicine · 2023 · PMC10500557 · PMID 37719418

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A prespecified meta-analysis of seven RCTs from the SURPASS program showed that treatment with all doses of tirzepatide for up to 104 weeks did not increase the risk of major CV events and actually showed a trend for reduction with respect to comparators. 44 No CV outcomes RCTs are planned for GLP-1RA plus SGLT-2i combination and GLP-1RA plus basal insulin FRC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.